Congenital toxoplasmosis: clinical, laboratory, and therapeutic considerations, with special reference to subclinical disease.
D000407:Alabama; D002493:Central Nervous System Diseases / Q000209:etiology; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007223:Infant; D007231:Infant, Newborn; D008607:Intellectual Disability / Q000209:etiology; D011247:Pregnancy; D011446:Prospective Studies; D011739:Pyrimethamine / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D014125:Toxoplasmosis, Congenital / Q000175:diagnosis / Q000453:epidemiology*
D002556:Cerebrospinal Fluid Proteins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D013449:Sulfonamides; D011739:Pyrimethamine